Contribution of Ca2+-dependent protein kinase C in the spinal cord to the development of mechanical allodynia in diabetic mice

Biological and Pharmaceutical Bulletin

Volumn 30, Issue 5, 2007, Pages 990-993

  Honda, Kenji ^a   Koguchi, Masako ^a   Koga, Kohei ^b   Nakajima, Kyoko ^a   Kobayashi, Fumito ^a   Migita, Keisuke ^a   Ogata, Shigenori ^a   Hirabara, Yasutoshi ^a   Takano, Yukio ^a  

^a FUKUOKA UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Ca2+ dependent protein kinase C; Diabetic mice; Mechanical allodynia; Spinal cord

Indexed keywords

1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; CALCIUM; CALPHOSTIN C; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PROTEIN KINASE C; PROTEIN KINASE C INHIBITOR;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; MALE; MOUSE; NONHUMAN; SPINAL CORD; STREPTOZOCIN DIABETES;

ANIMALS; BIOMECHANICS; CALCIUM; DIABETES MELLITUS, EXPERIMENTAL; HYPERALGESIA; INJECTIONS, SPINAL; MALE; MICE; MICE, INBRED STRAINS; PROTEIN KINASE C; SPINAL CORD;

EID: 34248202038     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.30.990     Document Type: Article

References (27)

1. Archer A. G., Watkins P. J., Thomas P. K., Sharma A. K., Payan J., J. Neurol. Neurosurg. Psychiatry, 46, 491-499 (1983).
2. Said G., J. Neurol., 243, 431-440 (1996).
3. Courteix C., Eschalier A., Lavarene J., Pain, 53, 81-88 (1993).
4. Kamei J., Ohhashi Y., Aoki T., Kawashima N., Kasuya Y., Brain Res., 571, 199-203 (1992).
5. Malcangio M., Tomlinson D. R., Pain, 76, 151-157 (1998).
6. Yamamoto T., Yaksh T. L., Pain, 49, 121-128 (1992).
7. Chaplan S. R., Malmberg A. B., Yaksh T. L., J. Pharmacol. Exp. Ther., 280, 829-838 (1997).
8. Chen L., Huang L. Y., Nature (London), 356, 521-523 (1992).
9. Mao J., Pice D. D., Phillips L. L., Lu J., Mayer D. J., Neurosci. Lett., 198, 75-78 (1995).
10. Ohsawa M., Kamei J., Eur. J. Pharmacol., 372, 221-228 (1999).
11. Ahlgren S. C., Levine J. D., J. Neurophysiol., 72, 684-692 (1994).
12. Koga K., Honda K., Ando S., Harasawa I., Takano Y., Kamiya H., Eur. J. Pharmacol., 505, 75-82 (2004).
13. Calcutt N. A., Chaplan S. R., Br. J. Pharmacol., 122, 1478-1482 (1997).
14. Hylden J. L. K., Wilcox G. L., Eur. J. Pharamacol., 67, 313-316 (1980).
15. Lowry O. H., Rosebrough N. J., Farr A. L., Randall R. J., J. Biol. Chem., 193, 265-275 (1951).
16. Kobayashi E., Nakano H., Morimoto M., Tamaoki T., Biochem. Biophys. Res. Commun., 159, 548-553 (1989).
17. Tamaoki T., Nakano H., Biotechnology, 8, 732-735 (1990).
18. Ahlgren S. C., Levine J. D., Neuroscience, 4, 1049-1055 (1993).
19. Miletic V., Bowen K. K., Miletic G., Neurosci. Lett., 288, 199-202 (2000).
20. Malmberg A. B., Brandon E. P., Idzerda R. L., Liu H., McKnigh G. S., Basbaum A. I., J. Neurosci., 17, 7462-7470 (1997a).
21. Malmberg A. B., Chen C., Tonegawa S., Basbaum A. I., Science, 278, 279-283 (1997b).
22. Yamagishi S., Uehara K., Otsuki S., Yagihashi S., J. Neurochem., 87, 497-507 (2003).
23. Kapur D., Diabetes Metab. Res. Rev., 19, S9-S15 (2003).
24. Gerber G., Kangrga I., Ryu P. D., Larew J. S., Randic M., J. Neurosci., 9, 3606-3617 (1989).
25. Brenner B. J., Ji R. R., Shaffer S., Woolf C. D., Eur. J. Neurosci., 20, 375-384 (2004).
26. Kawasaki Y., Kohno T., Zhuang Z. Y., Brenner J., Wang H., Van per Meer C., Befort K., Woolf C. J., Ji R. R., J. Neurosci., 24, 8310-8321 (2004).
27. Sluka K. A., Audette K. M., Molecular Pain, 2, 13, 1-23 (2006).